Further studies should reveal the interdependence of LMNA, STMN1, TrkA and MYCN and their suitability for targeted intervention, from which patients with MYCN-amplified high-risk NB would ultimately benefit in the future. This evidence concerns the gene STMN1 and neuroblastoma.